Pharmafile Logo
Pharmafocus logo
Advanced Search
hawthorn_eisai

Eisai poaches senior Pfizer and Sanofi execs for neurology group

April 26, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Eisai, Pfizer, Sanofi, appointments, hawthorne, zaim

Eisai has made new appointments to its US neurology business group, bringing in senior executives who have previously held positions …

Appointment
neil_lister_perrigo

Perrigo name new head of its combined UK and Ireland business

April 26, 2016
Sales and Marketing Ireland, Perrigo, UK, lister, neil, new head

Perrigo has named Neil Lister as the head of its newly-combined UK and Ireland business. The manufacturer and distributor of …

Appointment
george-freeman1

Northern Powerhouse life sciences contributing £10 billion to UK economy, says minister

April 26, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Jobs, Northern Powerhouse, contribution, economy, exporting, george freeman, investment, life sciences, minister, north

Minister for Life Sciences, George Freeman MP, has revealed that life sciences businesses within the Northern Powerhouse are contributing over …

News
clinicaltrial1

US panel says Sarepta’s trial DMD drug not proven effective

April 26, 2016
Manufacturing and Production, Research and Development DMD, US FDA, drug trial, sarepta

A US advisory committee has concluded Sarepta Therapeutics’ (Nasdaq: SRPT) trial drug to treat muscle wasting condition has not proved …

News
credit_bayerag

Bayer’s earnings beat estimates as blockbusters shine

April 26, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Eylea, Q1, Xarelto, blockbusters, growth, results, sales

Bayer (FWB: BAYN) has reported a 15.7% rise in underlying core earnings for the first quarter of 2016, with prescription …

News
astrazeneca_building_white

AstraZeneca’s COPD therapy gets US FDA approval

April 26, 2016
Research and Development, Sales and Marketing AstraZeneca, COPD, US FDA, drug approval

UK drug firm AstraZeneca (LSE: AZN) said the US Food and Drug Administration has approved its therapy to treat chronic …

News
allergan_waco

Allergan breaks ground on $200 million expansion at Texas site

April 26, 2016
Manufacturing and Production Allergan, doubling, expansion, eye care, facility, investment, manufacturing, size, texas, waco

Allergan (NYSE: AGN) has broken ground on a $200 million expansion at its manufacturing facility in Waco, Texas. The expansion …

News
novartis_mit_us

Novartis exploring almost $14-billion stake sale in Roche – reports

April 26, 2016
Manufacturing and Production, Sales and Marketing Financial, Merger & Acquisition, Novartis, Roche, Stake sale

Swiss pharma firm Novartis (VTX: NOVN) maybe looking at options to sell its one-third stake in cancer drugmaker Roche’s (VTX: …

News
gilead-sciences

EU grants approval for Gilead’s HIV treatment Descovy

April 26, 2016
Manufacturing and Production, Research and Development EU, HIV, approval, descovy, taf

Gilead Sciences (NASDAQ: GILD) has announced that the fixed-dose combination HIV treatment, Descovy (emtricitabine, tenofovir alafenamide), has been granted marketing …

News
joseph_papa

Valeant names Joseph Papa as new chief executive officer

April 25, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Chairman, Valeant, joseph papa, new, new ceo, papa, pearson

Valeant Pharmaceuticals has announced that Joseph C. Papa will succeed Michael Pearson as chairman and chief executive officer of the …

Appointment
test_results

FDA, WHO criticise integrity of data at contract research firm Semler

April 25, 2016
Research and Development, Sales and Marketing FDA, India, WHO, World Health Organisation, semler, semler research

The US Food and Drug Administration and the World Health Organisation have raised serious concerns related to violations of good …

News
stocks1

Weekly Movers: PTC Therapeutics, Celator Pharmaceuticals, Chiasma, Sarepta and more…

April 25, 2016
Research and Development, Sales and Marketing

With the earnings season in full swing this week investors focussed on the impact on stock moves as companies declared …

Feature

Pfizer, GSK’s anti-smoking drugs not linked to increase in serious neuropsychiatric adverse events – Study

April 25, 2016
Research and Development, Sales and Marketing

Pharma giant Pfizer’s (NYSE: PFE) smoking cessation drug Chantix (varenicline) did not show an increase in serious neuropsychiatric adverse events …

News
stocks2

Valeant receives further default notices due to its delayed 10-K filing

April 25, 2016
Medical Communications, Sales and Marketing Valeant, default, risk, trouble, worry

Valeant Pharmaceuticals has issued a statement detailing that they have received additional notices of default under indentures due to its …

News
sample

Merck’s colorectal cancer drug meets primary endpoint in Phase III study

April 25, 2016
Research and Development, Sales and Marketing Erbitux, Merck, Serono, cancer drugs, colorectal cancer, increased survival, oncology, phase 3, phase III

Merck (FWB: MRK) has announced that its Phase III clinical trial of Erbitux, in combination with Folfox, met its primary …

News
astrazeneca_sign_sky

AstraZeneca to sequence genomes to develop new drugs

April 22, 2016
Medical Communications, Sales and Marketing AstraZeneca, Finland, Wellcome Trust, collaboration, genome, genomics, human longevity, institute for molecular medicine, sanger institute

AstraZeneca (LSE: AZN) has announced an integrated genomics initiative that aims to transform the drug discovery and development across is …

News
trials

AbbVie announces further industry and academic collaborations

April 22, 2016
Medical Communications, Research and Development AbbVie, collaboration, commercialisation, cytomx, partnership, research, university of chicago

AbbVie (NYSE: ABBV) has announced further collaborations that will see it partner with industry and academia to develop oncology candidates …

News
biogen_logo

Biogen Q1 profits rise boosted by Tecfidera sales

April 22, 2016
Medical Communications, Sales and Marketing Biogen, Q1, biotech, earnings, results, tecfidera

Shares in Biogen (Nasdaq: BIIB) climbed to close up over 5% Thursday after the company reported 18% rise in first-quarter …

News
lab

Novartis muscular drug fails in Phase III trials

April 22, 2016
Medical Communications, Research and Development FDA, Novartis, bimagrumab, breakthrough, morphosys, muscular, phase III

A muscular drug developed by Novartis (NYSE: NVS), in partnership with MorphoSys (ETR: MOR), failed to meet its primary endpoint …

News
actelion_logo

Actelion ups outlook for 2016, reports Q1 net income up 12%

April 22, 2016
Medical Communications, Sales and Marketing Actelion, Biotechnology, Q1 results, earnings, outlook

Swiss biotech company Actelion (VTX: ATLN) raised its outlook for 2016 and reported a 12% rise in first quarter net …

News
The Gateway to Local Adoption Series

Latest content

Ofichem brings all brands under single trading name

April 23, 2026

Carvolix strengthens its Board of Directors, advisory board and governance structure

April 23, 2026

Under-Secretary of State for Health Innovation and Safety visits new building on University of Huddersfield’s NHIC

April 22, 2026

Incyclix Bio announces new additions to the Board

April 22, 2026

Remedy Plan Therapeutics Appoints Jotin Marango as CFO and CBO

April 21, 2026